European Medicines Agency puts brakes on Merck's Tredaptive
This article was originally published in Scrip
Executive Summary
No new patients should start treatment with Merck & Co's Tredaptive, approved for dyslipidaemia or primary hypercholesterolaemia, says the European Medicines Agency. The EMA has started a review of the safety and efficacy of the product in the wake of Merck's failed Phase III HSP2-THRIVE study.